

DEFINITIONS

Unless the context otherwise requires, explanations and definitions of certain terms used in this document in connection with our Company and our business shall have the meanings set out below. The terms and their meanings may not always correspond to standard industry meaning or usage of these terms.

“Accountants’ Report”	the accountants’ report prepared by Deloitte Touche Tohmatsu, set out in Appendix I to this document
“affiliate”	with respect to any specified person, any other person, controlling or controlled by or under direct or indirect common control with such specified person
“AFRC”	the Accounting and Financial Reporting Council of Hong Kong
“Articles of Association” or “Articles”	the articles of association of the Company adopted on September 12, 2025, effective upon the [REDACTED], summarized in Appendix V to this document
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Atom Australia”	Atom Therapeutics Pty Ltd, a company limited by shares established in Australia on June 26, 2020, and a wholly-owned subsidiary of our Company
“Atom U.S.”	Atom Therapeutics America Inc, a stock corporation established in California, U.S. on September 29, 2023, and a wholly-owned subsidiary of our Company
“Atom Zhenjiang”	Zhenjiang Atom Biomedical Co., Ltd. (鎮江新元素生物醫藥有限公司), a limited liability company established in the PRC on September 21, 2020, and a wholly-owned subsidiary of our Company
“Atom Zhongchi”	Taizhou Atom Zhongchi Management Consulting Partnership (Limited Partnership) (泰州元素眾持管理諮詢合夥企業(有限合夥)), a limited partnership established in the PRC on January 7, 2021, and our employee incentive platform
“Audit Committee”	audit committee of the Board
“Board” or “Board of Directors”	the board of Directors of our Company
“Business Day” or “business day”	a day on which banks in Hong Kong are generally open for normal business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong

[REDACTED]

DEFINITIONS

“China” or “PRC”	the People’s Republic of China, but for the purpose of this document and for geographical reference only and except where the context requires otherwise, references in this document to “China” and the “PRC” do not include Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“CMS”	China Medical System Holdings Limited (SEHK: 867; SGX: 8A8)
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended from time to time
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended from time to time
“Company”, “our Company”, or “Atom Therapeutics”	Atom Therapeutics Co., Ltd. (杭州新元素藥業股份有限公司), a limited liability company established in the PRC on March 9, 2012 and converted into a joint stock company with limited liability on May 28, 2025, and originally known as Zhenjiang Atom Therapeutics Co., Ltd. (鎮江新元素醫藥科技有限公司)
“Company Law” or “PRC Company Law”	the Company Law of the PRC (《中華人民共和國公司法》), as amended from time to time
“Compliance Advisor”	Somerley Capital Limited
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“connected transaction(s)”	has the meaning ascribed thereto under the Listing Rules
“Conversion of Unlisted Shares into H Shares”	the conversion of 36,190,755 Unlisted Shares into H Shares on a one-for-one basis upon the completion of [REDACTED]
“core connected person”	has the meaning ascribed thereto under the Listing Rules
“Core Product”	has the meaning ascribed thereto in Chapter 18A of the Listing Rules; for the purpose of this document, our Core Product refers to ABP-671
“CSDC”	China Securities Depository and Clearing Co., Ltd. (中國證券登記結算有限責任公司)
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)” or “our Director(s)”	the director(s) of our Company
“Dr. Shi”	Dr. Shi Dongfang (史東方), the chairperson of the Board, an executive Director, our chief executive officer and our Single Largest Shareholder
“EIT”	enterprise income tax

DEFINITIONS

“EIT Law” the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》), as amended from time to time

“Employee Incentive Scheme” the employee incentive scheme as adopted by our Company on October 21, 2022, the principal terms of which are summarized in “Appendix VI — Statutory and General Information — D. Employee Incentive Scheme”

“EU” European Union

“FDA” the United States Food and Drug Administration

“FIL” Foreign Investment Law of the PRC (《中華人民共和國外商投資法》)

[REDACTED]

“Frost & Sullivan” Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., an independent market research and consulting company

“Frost & Sullivan Report” a market research report prepared by Frost & Sullivan

[REDACTED]

“Greater China” Chinese Mainland, Hong Kong, the Macau Special Administrative Region, and Taiwan

“Group”, “our Group”, “our”, “we”
or “us” our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)

“H Share(s)” overseas [REDACTED] ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, which are to be [REDACTED] and [REDACTED] in HK dollars

[REDACTED]

DEFINITIONS

[REDACTED]

“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars,” “HK dollars” or “HK\$”	Hong Kong dollars, the lawful currency of Hong Kong

[REDACTED]

“IASB”	International Accounting Standards Board
“IFRS”	the IFRS Accounting Standards as issued by the IASB
“Independent Third Party(ies)”	an individual or a company which, to the best of our Directors’ knowledge, is not a connected person of our Company

[REDACTED]

DEFINITIONS

“Kaitai Capital”	Kaitai Capital (凱泰資本), and for the purpose of this document means a Sophisticated Investors comprising a group of Pre-[REDACTED] Investors, namely Hangzhou Kaitai Chengde Investment Partnership (Limited Partnership) (杭州凱泰成德投資合夥企業(有限合夥)) (currently known as Hangzhou Kaitai Chengde Venture Capital Partnership (Limited Partnership) (杭州凱泰成德創業投資合夥企業(有限合夥))) (“ Kaitai Chengde ”), Hangzhou Kaitai Zhisheng Equity Investment Partnership Enterprise (Limited Partnership) (杭州凱泰智生股權投資合夥企業(有限合夥)) (“ Kaitai Zhisheng ”), Xiamen Jinyuan Kaitai Zhanhong Health Growth Venture Capital Investment Partnership (Limited Partnership) (廈門金圓凱泰展鴻健康成長創業投資合夥企業(有限合夥)) (“ Jinyuan Kaitai ”), Nanjing Chuangyi Kaitai Venture Capital Partnership (Limited Partnership) (南京創熠凱泰創業投資合夥企業(有限合夥)) (“ Chuangyi Kaitai ”), Xiamen Yilian Kaitai Digital Venture Capital Fund Partnership (Limited Partnership) (廈門億聯凱泰數字創業投資合夥企業(有限合夥)) (“ Yilian Kaitai ”), Hangzhou Kaitai Hongze Venture Capital Partnership (Limited Partnership) (杭州凱泰宏澤創業投資合夥企業(有限合夥)) (“ Kaitai Hongze ”), Hangzhou Kaishi Venture Capital Partnership (Limited Partnership) (杭州凱實創業投資合夥企業(有限合夥)) (“ Kaishi Venture ”) and Xiamen Jinyuan Kaitai Zhanhong Health Growth Phase II Venture Capital Partnership (Limited Partnership) (廈門金圓凱泰展鴻健康成長二期創業投資合夥企業(有限合夥)) (“ Xiamen Jinyuan ”), each of which is a investment arms managed or advised by (杭州凱泰資本管理有限公司) or its affiliates
“Latest Practicable Date”	March 11, 2026, being the latest practicable date for the purpose of ascertaining certain information in this document prior to its publication
	[REDACTED]
“Listing Guide”	the Guide for New Listing Applicants published by the Stock Exchange, as amended from time to time
“Listing Rules” or “Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“MOFCOM” or “Ministry of Commerce”	the Ministry of Commerce of the PRC (中華人民共和國商務部)
“NASDAQ”	the Nasdaq Stock Market in the United States
“NDRC”	the National Development and Reform Commission (中華人民共和國國家發展和改革委員會)
“NMPA”	the National Medical Products Administration of the PRC (國家藥品監督管理局)

DEFINITIONS

“Nomination Committee”	nomination committee of the Board
“NPC”	the National People’s Congress of the PRC (中華人民共和國全國人民代表大會)

[REDACTED]

“Overseas Listing Trial Measures”	Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》), as amended from time to time
“PBOC”	the People’s Bank of China (中國人民銀行)
“PRC Legal Advisors”	AllBright Law Offices, the Company’s PRC legal advisors
“PRC Securities Law”	the Securities Law of the PRC (《中華人民共和國證券法》), as amended from time to time
“Pre-[REDACTED] Investment(s)”	the pre-[REDACTED] investment(s) in the Company undertaken by the Pre-[REDACTED] Investor(s) prior to the [REDACTED], details of which are set out in “History, Development and Corporate Structure — Pre-[REDACTED] Investments”
“Pre-[REDACTED] Investor(s)”	the investor(s) making investments in our Group prior to the [REDACTED], details of which are set out in “History, Development and Corporate Structure — Pre-[REDACTED] Investments”

[REDACTED]

“R&D”	research and development
-------	--------------------------

[REDACTED]

“Remuneration and Appraisal Committee”	remuneration and appraisal committee of the Board
--	---

DEFINITIONS

“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“SAFE”	the State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
“SAMR”	the State Administration for Market Regulation of the PRC (中華人民共和國國家市場監督管理總局)
“Securities and Futures Ordinance” or “SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
“SFC”	the Securities and Futures Commission of Hong Kong
“SGX”	Singapore Exchange Limited
“Share(s)”	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares
“Shareholder(s)”	holder(s) of our Share(s)
“Single Largest Shareholder”	Dr. Shi

[REDACTED]

“Sole Sponsor”	the sole sponsor as named in “Directors and Parties involved in the [REDACTED]”
----------------	---

[REDACTED]

“Sophisticated Investor(s)”	has the meaning ascribed to it under Chapter 2.3 of the Listing Guide
“SSE”	Shanghai Stock Exchange
“STA”	the State Taxation Administration (中華人民共和國國家稅務總局)

[REDACTED]

“State Council”	the State Council of the PRC (中華人民共和國國務院)
“Stock Exchange,” “Hong Kong Stock Exchange” or “SEHK”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules

DEFINITIONS

“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“SZSE”	Shenzhen Stock Exchange
“Takeovers Code”	the Codes on Takeovers and Mergers and Share Buy-backs, as amended from time to time
“TGA”	Therapeutic Goods Administration
“Track Record Period”	the years ended December 31, 2024 and 2025

[REDACTED]

“United States” or “U.S.”	the United States of America, its territories and possessions, any State of the United States, and the District of Columbia
“Unlisted Share(s)”	ordinary share(s) issued by our Company, with a nominal value of RMB1.00 each, which is/are not listed on any stock exchange
“U.S. dollars,” “US\$” or “USD”	United States dollars, the lawful currency of the United States
“U.S. Securities Act”	the United States Securities Act of 1933, as amended from time to time
“VAT”	value added tax

[REDACTED]

“%”	per cent
-----	----------

For ease of reference, the names of Chinese laws and regulations, governmental authorities, institutions, natural persons or other entities (including certain of our subsidiaries) have been included in this document in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail. English translations of company names and other terms from the Chinese language are provided for identification purposes only.